Ibalizumab

CAS No. 680188-33-4

Ibalizumab( —— )

Catalog No. M36665 CAS No. 680188-33-4

Ibalizumab(TMB-355) is a humanized IgG4 monoclonal antibody that acts as a CD4 receptor inhibitor, blocking the entry of HIV-1 into cells by binding to the CD4 receptor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 1198 Get Quote
5MG 1881 Get Quote
10MG 2537 Get Quote
25MG 3643 Get Quote
50MG 4922 Get Quote
100MG 6498 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Ibalizumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Ibalizumab(TMB-355) is a humanized IgG4 monoclonal antibody that acts as a CD4 receptor inhibitor, blocking the entry of HIV-1 into cells by binding to the CD4 receptor.
  • Description
    Ibalizumab (TMB-355) is a humanised IgG4 monoclonal antibody that prevents HIV cell entry by binding to CD4 receptor. Ibalizumab has the potential for HIV-1 infection research.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Microbiology/Virology
  • Target
    HIV
  • Recptor
    HIV Protease
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    680188-33-4
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Anthony Markham. Ibalizumab: First Global Approval. Drugs. 2018 May;78(7):781-785. ?
molnova catalog
related products
  • Saquinavir mesylate

    Apotent and selective inhibitor of HIV-1 protease with IC50 of 0.5-6 nM in cell assays.

  • Terameprocol

    Terameprocol is a synthetic tetra-methylated derivative of nordihydroguaiaretic acid (NDGA) and transcriptional inhibitor with potential antiviral, antiangiogenic, and antineoplastic activities. Terameprocol showed the strongest anti-HIV activity.

  • BMS-955176

    BMS-955176 (GSK-3532795) is a second-generation HIV-1 maturation inhibitor that exhibits potent activity (EC50=3.9±3.4 nM) against a library (n=87) of gag/pr recombinant viruses.